Organon & Co. (NYSE:OGN) Receives Consensus Rating of "Reduce" from Brokerages

Key Points

• Analyst consensus: Organon has an average rating of "Reduce" from seven analysts (five sell, one hold, one strong buy) with a 12‑month average price target of $8.50.
• The company missed Q4 estimates, reporting EPS of $0.63 vs. a $0.73 consensus and revenue of $1.51B (down 5.3% year‑over‑year); the stock trades around $6.01 with a market cap of $1.56B and a PE of 8.47.
• Organon pays a quarterly dividend of $0.02 (annualized $0.08, yield ~1.3%) and is majority‑held by institutions (~77.4%), though its reported debt‑to‑equity is notably high at about 11.47.

Organon & Co. (NYSE:OGN - Get Free Report) has received an average rating of "Reduce" from the seven ratings firms that are covering the company, MarketBeat Ratings reports. Five analysts have rated the stock with a sell rating, one has issued a hold rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $8.50.

Several equities analysts have recently weighed in on the stock. Zacks Research downgraded shares of Organon & Co. from a "hold" rating to a "strong sell" rating in a research note on Thursday, January 29th. Barclays increased their price objective on shares of Organon & Co. from $7.50 to $8.00 and gave the company an "underweight" rating in a report on Tuesday, February 24th. Finally, Wall Street Zen lowered shares of Organon & Co. from a "buy" rating to a "hold" rating in a research note on Saturday, January 31st.

Organon & Co. Price Performance

Shares of NYSE:OGN traded down $0.05 during trading on Friday, reaching $6.01. The stock had a trading volume of 238,874 shares, compared to its average volume of 4,971,729. The company has a debt-to-equity ratio of 11.47, a quick ratio of 1.23 and a current ratio of 1.82. Organon & Co. has a 1-year low of $5.76 and a 1-year high of $14.94. The stock has a market cap of $1.56 billion, a PE ratio of 8.47, a PEG ratio of 0.56 and a beta of 0.60. The business has a fifty day moving average price of $7.53 and a 200-day moving average price of $8.08.

Organon & Co. (NYSE:OGN - Get Free Report) last posted its quarterly earnings data on Thursday, February 12th. The company reported $0.63 EPS for the quarter, missing the consensus estimate of $0.73 by ($0.10). Organon & Co. had a net margin of 3.01% and a return on equity of 122.01%. The firm had revenue of $1.51 billion during the quarter, compared to analyst estimates of $1.52 billion. During the same period in the prior year, the company posted $0.90 earnings per share. The firm's revenue for the quarter was down 5.3% compared to the same quarter last year. On average, equities analysts forecast that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 12th. Shareholders of record on Monday, February 23rd were paid a dividend of $0.02 per share. The ex-dividend date of this dividend was Monday, February 23rd. This represents a $0.08 dividend on an annualized basis and a yield of 1.3%. Organon & Co.'s payout ratio is 11.27%.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Foster Dykema Cabot & Partners LLC purchased a new stake in shares of Organon & Co. in the third quarter valued at about $29,000. Farther Finance Advisors LLC grew its stake in shares of Organon & Co. by 87.8% in the 4th quarter. Farther Finance Advisors LLC now owns 4,349 shares of the company's stock valued at $31,000 after buying an additional 2,033 shares during the period. Rothschild Investment LLC increased its holdings in shares of Organon & Co. by 73.1% during the 3rd quarter. Rothschild Investment LLC now owns 3,899 shares of the company's stock worth $42,000 after buying an additional 1,646 shares during the last quarter. Eurizon Capital SGR S.p.A. acquired a new stake in shares of Organon & Co. during the 4th quarter worth approximately $44,000. Finally, Kestra Advisory Services LLC purchased a new stake in shares of Organon & Co. during the 4th quarter valued at approximately $47,000. Hedge funds and other institutional investors own 77.43% of the company's stock.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.